Compound interferon inducing agent lozenge

Abstract

The present invention is compound interferon inducing agent lozenge, relates to biomedicine engineering, and aims at providing lozenge capable of inducing body to generate endogenous interferon and with high curative effect, less side effect, small dosage and wide application. Each of the compound interferon inducing agent lozenge contains attenuated Newcastle disease virus vaccine or deactivated Newcastle disease virus vaccine 10-120 hemagglutination units, astragalus root 1-2000 mg, liquiritigenin 1-1000 mg, supplementary material and stabilizer. The compound interferon inducing agent lozenge is suitable for preventing SARS and other viral infectious respiratory tract diseases, and has also auxiliary treatment effect on various kinds of tumor, hepatitis B and hepatitis C.

Description

technical field

[0001] The invention relates to the technical field of medical bioengineering. Especially endogenous interferon inducer in cell bioengineering. Background technique

[0002] The interferon system is a ubiquitous system in living organisms. It is a defensive substance produced by the body itself to resist the invasion of foreign viruses and maintain the self-stabilization of the body or cells. Inhibiting virus replication and reproduction is one of the most basic and common properties of interferon, which is effective for almost all human pathogenic viruses. In the process of virus infection, the production of interferon is a common phenomenon, and the interferon produced by a virus infection can produce resistance to many viruses.

[0003] Because interferon has multiple biological effects such as broad-spectrum antiviral and immune regulatory responses, more than 40 countries have approved the use of interferon preparations to treat more than 30 diseases, ...